Compare Stocks: ARVN, NUVB, BHVN, and PHVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$9.39	$8.68	$6.97 ▼ $14.51	$605.84M	1.75	584,827 shs	449,296 shs
BHVN Biohaven	$15.69	$14.86	$7.48 ▼ $18.57	$2.37B	1.28	3.09 million shs	1.90 million shs
NUVB Nuvation Bio	$6.79 -0.3%	$6.35	$2.99 ▼ $9.75	$2.38B	1.52	5.25 million shs	3.76 million shs
PHVS Pharvaris	$35.25	$34.78	$20.65 ▼ $38.13	$2.31B	-2.33	652,252 shs	483,574 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	+2.29%	+7.31%	+31.33%	+19.92%
BHVN Biohaven	0.00%	+1.82%	+6.95%	+41.11%	-1.03%
NUVB Nuvation Bio	0.00%	+1.34%	+2.80%	+41.31%	+74.95%
PHVS Pharvaris	0.00%	-0.20%	+0.97%	+11.59%	+52.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$9.39	$8.68	$6.97 ▼ $14.51	$605.84M	1.75	584,827 shs	449,296 shs
BHVN Biohaven	$15.69	$14.86	$7.48 ▼ $18.57	$2.37B	1.28	3.09 million shs	1.90 million shs
NUVB Nuvation Bio	$6.79 -0.3%	$6.35	$2.99 ▼ $9.75	$2.38B	1.52	5.25 million shs	3.76 million shs
PHVS Pharvaris	$35.25	$34.78	$20.65 ▼ $38.13	$2.31B	-2.33	652,252 shs	483,574 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	+2.29%	+7.31%	+31.33%	+19.92%
BHVN Biohaven	0.00%	+1.82%	+6.95%	+41.11%	-1.03%
NUVB Nuvation Bio	0.00%	+1.34%	+2.80%	+41.31%	+74.95%
PHVS Pharvaris	0.00%	-0.20%	+0.97%	+11.59%	+52.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.27	Hold	$14.17	50.87% Upside
BHVN Biohaven	2.65	Moderate Buy	$18.94	20.70% Upside
NUVB Nuvation Bio	2.69	Moderate Buy	$13.00	91.46% Upside
PHVS Pharvaris	2.86	Moderate Buy	$51.08	44.90% Upside

Current Analyst Ratings Breakdown

Latest ARVN, NUVB, BHVN, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/28/2026	BHVN Biohaven	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/28/2026	BHVN Biohaven	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
8/27/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/26/2026	BHVN Biohaven	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$30.00
8/21/2026	NUVB Nuvation Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/18/2026	NUVB Nuvation Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/14/2026	PHVS Pharvaris	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
8/14/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$262.60M	2.31	N/A	N/A	$6.76 per share	1.39
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
NUVB Nuvation Bio	$62.90M	37.90	N/A	N/A	$0.88 per share	7.72
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$80.80M	$0.10	93.91	N/A	N/A	2.94%	1.91%	1.29%	11/4/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/2/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)

Latest ARVN, NUVB, BHVN, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	7.91	7.91
BHVN Biohaven	21.23	4.73	4.73
NUVB Nuvation Bio	0.96	8.37	8.14
PHVS Pharvaris	N/A	11.94	11.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
BHVN Biohaven	88.78%
NUVB Nuvation Bio	61.67%
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	7.30%
BHVN Biohaven	13.80%
NUVB Nuvation Bio	30.11%
PHVS Pharvaris	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	64.52 million	59.81 million	Optionable
BHVN Biohaven	239	151.04 million	130.20 million	Optionable
NUVB Nuvation Bio	60	351.12 million	245.40 million	Optionable
PHVS Pharvaris	30	65.41 million	N/A	Not Optionable

ARVN, NUVB, BHVN, and PHVS Headlines

Recent News About These Companies

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It (PHVS)

...

September 6 at 9:20 AM | marketbeat.com

Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 4 at 4:28 AM | marketbeat.com

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

September 3, 2026 | globenewswire.com

Pharvaris N.V. $PHVS Shares Purchased by Wellington Management Group LLP

September 3, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS

September 3, 2026 | marketbeat.com

Pharvaris N.V. (NASDAQ:PHVS) Short Interest Up 48.7% in August

September 1, 2026 | marketbeat.com

Moore Capital Management LP Buys Shares of 44,001 Pharvaris N.V. $PHVS

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Purchases 281,829 Shares of Pharvaris N.V. $PHVS

September 1, 2026 | marketbeat.com

Deutsche Bank AG Purchases Shares of 53,469 Pharvaris N.V. $PHVS

August 29, 2026 | marketbeat.com

venBio Partners LLC Invests $160.57 Billion in Pharvaris N.V. $PHVS

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Buys 457,804 Shares of Pharvaris N.V. $PHVS

August 27, 2026 | marketbeat.com

525,750 Shares in Pharvaris N.V. $PHVS Purchased by Elmind Capital LP

August 26, 2026 | marketbeat.com

5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS

August 26, 2026 | marketbeat.com

105,528 Shares in Pharvaris N.V. $PHVS Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - What's Next?

August 25, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Hits New 12-Month High - What's Next?

August 21, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock

August 19, 2026 | insidertrades.com

Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares

August 18, 2026 | marketbeat.com

What is HC Wainwright's Forecast for Pharvaris Q3 Earnings?

August 18, 2026 | marketbeat.com

Research Analysts Issue Forecasts for Pharvaris Q4 Earnings

August 17, 2026 | marketbeat.com

Pharvaris (PHVS) Gets a Hold from Bank of America Securities

August 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, NUVB, BHVN, and PHVS Company Descriptions

Arvinas NASDAQ:ARVN

$9.39 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Biohaven NYSE:BHVN

$15.69 0.00 (0.00%)

As of 09/4/2026 03:58 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Nuvation Bio NYSE:NUVB

$6.79 -0.02 (-0.29%)

As of 09/4/2026 03:58 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Pharvaris NASDAQ:PHVS

$35.25 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, NUVB, BHVN, and PHVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, NUVB, BHVN, and PHVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, NUVB, BHVN, and PHVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, NUVB, BHVN, and PHVS Company Descriptions

Arvinas NASDAQ:ARVN

Biohaven NYSE:BHVN

Nuvation Bio NYSE:NUVB

Pharvaris NASDAQ:PHVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, NUVB, BHVN, and PHVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, NUVB, BHVN, and PHVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, NUVB, BHVN, and PHVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, NUVB, BHVN, and PHVS Company Descriptions

Arvinas NASDAQ:ARVN

Biohaven NYSE:BHVN

Nuvation Bio NYSE:NUVB

Pharvaris NASDAQ:PHVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools